Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Remdesivir versus Interferon beta-1a + Remdesivir in the Treatment of COVID-19
IRCT20200721048159N4Phase 3Completed
- Sponsor
- Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences
- Start
- Jul 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of remdesivir and interferon beta-1a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences. Started Jul 2021; status: completed.
02
Drugs
remdesivirinterferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200721048159N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200721048159N4.